Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Subscribe To Our Newsletter & Stay Updated
